



Atty. Docket No. MSE-2610

PATENT

TECH CENTER 1600/2900

NOV 0 7 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rehm et al.

Serial No.: 09/844,815

Group Art Unit: 1641

Filed: April 30, 2001

Examiner: Counts, Gary W.

For: URINARY TRYPSIN INHIBITOR ASSAY CONTAINING A  
CHELATING AGENT

\*\*\*\*\*

CERTIFICATION UNDER 37 CFR § 1.8(a)

I hereby certify that, on the date shown below, this correspondence, and any attachments referred to herein, are being deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 under 37 CFR § 1.8(a) with sufficient postage as first class mail.

  
Gayle Gestick

10/28/03  
Date

\*\*\*\*\*

**SUPPLEMENTAL**  
**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56, §1.97 AND §1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The citation listed on the enclosed Supplemental Information Disclosure Statement (modified Form PTO-1449) may be material to the examination of the above-identified patent application. Therefore, Applicant submits this document in compliance with the duty of disclosure as defined in 37 CFR §1.56, §1.97, and §1.98. The Examiner is requested to make this citation of official record in the present application.

Legible copies of all items listed in the attached modified Form PTO-1449 accompany this information statement.

The present information disclosure statement is being filed after the mailing date of a final Office Action under 37 CFR § 1.113 but before the payment of the issue fee. A fee of \$180.00 as set forth in 37 CFR § 1.17(p) and a Statement under 37 CFR § 1.97(e) is required.


I hereby certify that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the best of my knowledge after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR § 1.97(e)(2).

The Commissioner is hereby authorized to charge the required fee of \$180.00 to Deposit Account No. 50-0781. A duplicate of this transmittal is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required under this submission, or credit any overpayment, to Deposit Account 50-0781.

This information disclosure statement under 37 CFR §1.56, §1.97 and §1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 USC §102 or §103.

Respectfully submitted,

By:

  
Elizabeth A. Levy  
Attorney for Applicants  
Reg. No.34,375

Date: 28 OCT 2003

BAYER HEALTHCARE LLC  
63 North Street  
Medfield, MA 02052  
Tel: (508) 359-3876  
Fax: (508) 359-3885

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Page 1 of 1

Application No.	09/844,815
Filing Date	April 30, 2001
Inventor	Rehm et al.
Group Art Unit	1641
Examiner Name	Counts, Gary W.
Attorney Docket No.	MSE-2610

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Issue Date	Name of Patentee	Relevant Pages
		6,583,108	June 24, 2003	Tamburini et al.	Whole document

**RECEIVED**  
NOV 06 2003  
TECH CENTER 1800/2900

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Public. Date	Name of Patentee	Relevant Pages	Translation Yes/No

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Name of author (CAPITAL LETTERS), title of article (when appropriate), title of item (book, magazine, journal, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner Signature

Date Considered

Examiner: Initial if citation is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.